For research use only. Not for therapeutic Use.
Etofenamate（Cat No.:I003074）is a non-steroidal anti-inflammatory drug (NSAID) used topically to relieve pain and inflammation associated with conditions like osteoarthritis, muscle strains, and sports injuries. It works by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are responsible for producing prostaglandins—molecules involved in inflammation and pain. Etofenamate is applied directly to the skin over the affected area, offering localized relief with a lower risk of systemic side effects compared to oral NSAIDs. It is available in various formulations, such as creams and gels, for ease of use.
| Catalog Number | I003074 |
| CAS Number | 30544-47-9 |
| Molecular Formula | C18H18F3NO4 |
| Purity | ≥95% |
| Target | COX |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate |
| InChI | InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2 |
| InChIKey | XILVEPYQJIOVNB-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)C(=O)OCCOCCO)NC2=CC=CC(=C2)C(F)(F)F |
| Reference | </br>1:Effectiveness of etofenamate for treatment of knee osteoarthritis: a randomized controlled trial. Güner S, Gökalp MA, Gözen A, Ünsal SŞ, Güner Şİ.Ther Clin Risk Manag. 2016 Nov 14;12:1693-1699. eCollection 2016. PMID: 27881922 Free PMC Article</br>2:Novel Drug Delivery System For Dermal Uptake Of Etofenamate: Semisolid SLN Dispersion. Badilli U, Sengel-Turk CT, Amasya G, Tarimci N.Curr Drug Deliv. 2016 Aug 8. [Epub ahead of print] PMID: 27501715 </br>3:Analytical Quality by Design Approach in RP-HPLC Method Development for the Assay of Etofenamate in Dosage Forms. Peraman R, Bhadraya K, Reddy YP, Reddy CS, Lokesh T.Indian J Pharm Sci. 2015 Nov-Dec;77(6):751-7. PMID: 26997704 Free PMC Article</br>4:Prolonged localized photosensitivity following allergic and photo-aggravated contact dermatitis from etofenamate. Espasandín-Arias M, Vázquez-Osorio I, Salgado-Boquete L, Rodríguez-Granados MT, Toribio J.Photodermatol Photoimmunol Photomed. 2014 Dec;30(6):340-2. doi: 10.1111/phpp.12130. Epub 2014 Aug 13. No abstract available. PMID: 25040936 </br>5:Development of etofenamate-loaded semisolid sln dispersions and evaluation of anti-inflammatory activity for topical application. Badilli U, Sengel-Turk CT, Onay-Besikci A, Tarimci N.Curr Drug Deliv. 2015;12(2):200-9. PMID: 24925321 </br>6:Topical gels of etofenamate: in vitro and in vivo evaluation. Marto J, Baltazar D, Duarte A, Fernandes A, Gouveia L, Militão M, Salgado A, Simões S, Oliveira E, Ribeiro HM.Pharm Dev Technol. 2015;20(6):710-5. doi: 10.3109/10837450.2014.915571. Epub 2014 May 5. PMID: 24798887 </br>7:Development and Validation of a Stability-Indicating Assay of Etofenamate by RP-HPLC and Characterization of Degradation Products. Peraman R, Nayakanti D, Dugga HH, Kodikonda S.Sci Pharm. 2013 Jul 22;81(4):1017-28. doi: 10.3797/scipharm.1305-19. Print 2013 Oct-Dec. PMID: 24482770 Free PMC Article</br>8:Adverse reaction of topical etofenamate: petechial eruption. Orbak Z, Yildirim ZK, Sepetci O, Karakelleoglu C, Alp H.West Indian Med J. 2012 Oct;61(7):767-9. PMID: 23620980 </br>9:[Acute inferior myocardial infarction after injection of etofenamate]. Tekin YK, Tekin G.Turk Kardiyol Dern Ars. 2012 Dec;40(8):733-5. doi: 10.5543/tkda.2012.03592. Turkish. PMID: 23518891 Free Article</br>10:Action spectrum for etofenamate photoallergic contact dermatitis. Kerr A, Becher G, Ibbotson S, Ferguson J.Contact Dermatitis. 2011 Aug;65(2):117-8. doi: 10.1111/j.1600-0536.2011.01920.x. No abstract available. PMID: 21745218 |
